159 related articles for article (PubMed ID: 29274617)
21. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
22. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Chlebowski RT; Col N
Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
[TBL] [Abstract][Full Text] [Related]
23. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Boccardo F; Guglielmini P; Bordonaro R; Fini A; Massidda B; Porpiglia M; Roagna R; Serra P; Orzalesi L; Ucci G; Rubagotti A
Eur J Cancer; 2013 May; 49(7):1546-54. PubMed ID: 23415888
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
25. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
26. Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.
Bergen ES; Berghoff AS; Medjedovic M; Rudas M; Fitzal F; Bago-Horvath Z; Dieckmann K; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
Clin Cancer Res; 2019 May; 25(9):2737-2744. PubMed ID: 30647078
[TBL] [Abstract][Full Text] [Related]
27. Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Desmedt C; Zoppoli G; Gundem G; Pruneri G; Larsimont D; Fornili M; Fumagalli D; Brown D; Rothé F; Vincent D; Kheddoumi N; Rouas G; Majjaj S; Brohée S; Van Loo P; Maisonneuve P; Salgado R; Van Brussel T; Lambrechts D; Bose R; Metzger O; Galant C; Bertucci F; Piccart-Gebhart M; Viale G; Biganzoli E; Campbell PJ; Sotiriou C
J Clin Oncol; 2016 Jun; 34(16):1872-81. PubMed ID: 26926684
[TBL] [Abstract][Full Text] [Related]
28. Exemestane for breast-cancer prevention in postmenopausal women.
Goss PE; Ingle JN; Alés-Martínez JE; Cheung AM; Chlebowski RT; Wactawski-Wende J; McTiernan A; Robbins J; Johnson KC; Martin LW; Winquist E; Sarto GE; Garber JE; Fabian CJ; Pujol P; Maunsell E; Farmer P; Gelmon KA; Tu D; Richardson H;
N Engl J Med; 2011 Jun; 364(25):2381-91. PubMed ID: 21639806
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
31. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
32. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
[TBL] [Abstract][Full Text] [Related]
33. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
34. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Freedman OC; Amir E; Hanna W; Kahn H; O'Malley F; Dranitsaris G; Cole DE; Verma S; Folkerd E; Dowsett M; Clemons M
Breast Cancer Res Treat; 2010 Jan; 119(1):155-61. PubMed ID: 19731013
[TBL] [Abstract][Full Text] [Related]
36. [Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Sakurai T; Oura S; Hirai I; Tanino H; Yoshimas T; Kokawa Y; Nishida M; Sasaki R; Kinoshita T; Bessho T; Yokochi H; Nishimura O; Okamura Y
Gan To Kagaku Ryoho; 2004 Nov; 31(12):2051-3. PubMed ID: 15570939
[TBL] [Abstract][Full Text] [Related]
37. Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Chapman JA; Shepherd LE; Ingle JN; Muss HB; Pritchard KI; Gelmon KA; Whelan TJ; Elliott C; Goss PE
Breast Cancer Res Treat; 2016 Apr; 156(2):343-9. PubMed ID: 27006189
[TBL] [Abstract][Full Text] [Related]
38. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Iaffaioli RV; Formato R; Tortoriello A; Del Prete S; Caraglia M; Pappagallo G; Pisano A; Gebbia V; Fanelli F; Ianniello G; Cigolari S; Pizza C; Marano O; Pezzella G; Pedicini T; Febbraro A; Incoronato P; Manzione L; Ferrari E; Marzano N; Quattrin S; Pisconti S; Nasti G; Giotta G; Colucci G;
Br J Cancer; 2005 May; 92(9):1621-5. PubMed ID: 15856035
[TBL] [Abstract][Full Text] [Related]
40. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
